Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancer.

bioRxiv : the preprint server for biology·2026
Same author

Development of a multiplex assay for early detection of pancreatic cancer in high-risk groups.

BMC cancer·2026
Same author

Computational modeling-directed combination treatment with etanercept and mifepristone mitigates neuroinflammation in a mouse model of Gulf War Illness.

PloS one·2026
Same author

Affordable, cleanroom-free millifluidic production of targeted lipid nanocarriers <i>via</i> additive manufacturing.

Lab on a chip·2026
Same author

Restricting metabolic plasticity enhances stress adaptation through the modulation of PDH and HIF1A in TRAP1-depleted colon cancer.

Cancer letters·2025
Same author

Imaging Cell Surface Plectin in PDAC Patients - A First-In-Human Phase 0 Study Report.

Molecular imaging and biology·2025

Related Experiment Video

Updated: May 16, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Metastatic biomarker discovery through proteomics.

Lindsey T Brinton1, Teresa A Brentnall, Jeffrey A Smith

  • 1Department of Biomedical Engineering, University of Virginia School of Engineering and Applied Sciences, PO Box 800759, Health System, Charlottesville, VA 22908, USA.

Cancer Genomics & Proteomics
|November 20, 2012
PubMed
Summary
This summary is machine-generated.

Identifying reliable biomarkers is crucial for predicting cancer metastasis and improving patient outcomes. This review explores proteomic technologies and potential biomarkers to advance personalized cancer medicine.

More Related Videos

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

Related Experiment Videos

Last Updated: May 16, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
08:08

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors

Published on: February 27, 2015

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer
12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

Area of Science:

  • Oncology and Proteomics

Background:

  • Tumor heterogeneity complicates effective cancer treatment development.
  • Personalized medicine aims to match therapies to individual tumor pathways for better prognosis.
  • Predicting tumor metastatic potential is critical for clinical management.

Purpose of the Study:

  • To review proteomic technologies for cancer biomarker discovery.
  • To discuss existing and potential metastatic biomarkers across various cancers.
  • To explore future directions for clinical translation of these biomarkers.

Main Methods:

  • Review of current proteomic technologies.
  • Analysis of existing literature on cancer biomarkers related to metastasis.
  • Discussion of challenges and opportunities in biomarker development.

Main Results:

  • Proteomic characterization efforts have primarily focused on early detection, with fewer on metastasis prediction.
  • Various potential biomarkers for metastasis exist but require further validation.
  • Significant advancements are needed to translate biomarker research into clinical practice.

Conclusions:

  • Developing biomarkers to predict and characterize metastasis is essential for advancing cancer care.
  • Proteomic technologies offer powerful tools for identifying such biomarkers.
  • Bridging the gap between research and clinical application is a key future challenge.